Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following progression on first-line gemcitabine-containing therapy with metastatic pancreatic ductal adenocarci...

Descripción completa

Detalles Bibliográficos
Autores principales: Hecht, J. Randolph, Lonardi, Sara, Bendell, Johanna, Sim, Hao-Wen, Macarulla, Teresa, Lopez, Charles D., Van Cutsem, Eric, Muñoz Martin, Andres J., Park, Joon Oh, Greil, Richard, Wang, Hong, Hozak, Rebecca R., Gueorguieva, Ivelina, Lin, Yong, Rao, Sujata, Ryoo, Baek-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078437/
https://www.ncbi.nlm.nih.gov/pubmed/33555926
http://dx.doi.org/10.1200/JCO.20.02232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078437/
https://www.ncbi.nlm.nih.gov/pubmed/33555926
http://dx.doi.org/10.1200/JCO.20.02232

Ejemplares similares